HAEHaemonetics Corporation

Haemonetics Corporation (NYSE: HAE) | Price: $117.78 | Today's Change: -5.10%

---

What Happened

Haemonetics filed an 8-K with the SEC on November 5, 2026, disclosing its second-quarter fiscal year 2027 financial results (Items 2.02 and 9.01). The company reported revenue of $648.7 million for Q2 FY2027, alongside net income of $34.0 million and operating income of $112.4 million. Diluted earnings per share came in at $1.51, with basic EPS at $1.52, reflecting a quarter that generated meaningful operating leverage relative to its net income line.

---

Why It Matters

For investors, the Q2 FY2027 results give a concrete read on how Haemonetics is performing at scale. Key points to note:

• Revenue of $648.7M represents the company's reported top-line result for the quarter — a material figure for a business of Haemonetics' scope in blood management and vascular closure solutions.
• Operating income of $112.4M implies an operating margin of approximately 17.3% on the quarter's revenue, suggesting the core business is generating solid profitability at the operating level.
• Net income of $34.0M is notably lower than operating income, indicating meaningful items below the operating line — such as interest expense, taxes, or other non-operating charges — that investors should scrutinize in the full filing detail.
• Diluted EPS of $1.51 provides the per-share earnings context that many investors use as a headline benchmark.
• Shares are trading lower by 5.10% on the day of this report, suggesting the market's reaction to these results — or to accompanying guidance or commentary — has been negative, though the specific source of that pressure is not determinable from the structured XBRL data alone.

This report follows StockWatch's existing coverage of Haemonetics, initiated on October 8, 2026. Investors may wish to reference that research for broader context on the company's strategic positioning.

---

Analysis

The gap between operating income ($112.4M) and net income ($34.0M) is the most striking feature of this Q2 FY2027 disclosure. An operating-to-net compression of that magnitude — roughly $78 million absorbed below the operating line — warrants close attention. Whether this reflects elevated interest costs, a tax event, restructuring charges, or other non-recurring items is not determinable from the XBRL data alone, but it is precisely the kind of detail that often drives a stock's reaction to an earnings release.

The -5.10% intraday decline in HAE shares is worth watching. At a current price of $117.78, the stock is trading in close proximity to the $118.00 figure referenced in StockWatch's October 2026 coverage — a coincidence that underscores how sensitive the valuation is to earnings delivery at this level.

What to watch next:

• Management commentary and guidance provided alongside the 8-K filing or on any accompanying earnings call, as these will clarify whether the below-the-line charges are one-time or structural.
• Segment-level revenue breakdown, which is not provided in the structured XBRL data but will be critical for understanding where top-line momentum is concentrated.
• Full cash flow statement, to assess whether the net income compression has a cash-equivalent impact or is primarily accounting-driven.

Overall, the operating income figure suggests the underlying business remains operationally sound, but the disconnect with net income and the negative share reaction are signals that warrant a careful read of the full filing.

---

Disclaimer

This report is a news and informational analysis of a public SEC filing. It does not constitute investment advice, a recommendation to buy or sell any security, or an offer or solicitation of any kind. All financial figures cited are sourced directly from Haemonetics' official XBRL filing data as reported to the SEC. Investors should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.

Existing Coverage

StockWatch has full coverage on HAE, published 2026-10-08. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/313143/000031314326000150/hae-20261105.htm